SciClone Pharmaceuticals Company Profile (NASDAQ:SCLN)

About SciClone Pharmaceuticals

SciClone Pharmaceuticals logoSciClone Pharmaceuticals, Inc. is a pharmaceutical company. The Company's product portfolio of therapies includes oncology, infectious diseases and cardiovascular disorders. The Company operates in two segments: China and the Rest of the World, including its operations in the United States and Hong Kong. The Company's lead product ZADAXIN (thymalfasin) is approved in approximately 30 countries, which is used for the treatment of hepatitis B virus (HBV), hepatitis C virus (HCV), and certain cancers according to the local regulatory approvals, and for use as an immune system enhancer. In addition to ZADAXIN, the Company markets approximately seven partnered and in-licensed products in China. The Company's development portfolio includes Angiomax, Neucardin, Loramyc, Cleviprex, RapidFilm, VIBATIV and SGX942. The Company sells ZADAXIN in various international markets through its subsidiary, SciClone Pharmaceuticals International Ltd. (SPIL).

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Drug Manufacturers - Other
  • Sub-Industry: Pharmaceuticals
  • Exchange: NASDAQ
  • Symbol: SCLN
  • CUSIP: 80862K10
Key Metrics:
  • Previous Close: $9.85
  • 50 Day Moving Average: $10.23
  • 200 Day Moving Average: $11.81
  • 52-Week Range: $7.35 - $15.03
  • Trailing P/E Ratio: 13.29
  • Foreward P/E Ratio: 14.49
  • P/E Growth: 0.00
  • Market Cap: $491.90M
  • Outstanding Shares: 49,939,000
  • Beta: 1.47
  • Net Margins: 24.02%
  • Return on Equity: 24.43%
  • Return on Assets: 21.08%
  • Current Ratio: 7.84%
  • Quick Ratio: 7.31%
Additional Links:
Companies Related to SciClone Pharmaceuticals:

Analyst Ratings

Consensus Ratings for SciClone Pharmaceuticals (NASDAQ:SCLN) (?)
Ratings Breakdown: No ratings tracked in the last 12 months.
Consensus Rating:N/A (Score: NaN)
Consensus Price Target: N/A

Analysts' Ratings History for SciClone Pharmaceuticals (NASDAQ:SCLN)
DateFirmActionRatingPrice TargetDetails
7/9/2015BWS FinancialDowngradeHold -> SellView Rating Details
6/29/2015MLV & Co.Initiated CoverageBuyView Rating Details
1/6/2015AegisReiterated RatingPositiveView Rating Details
(Data available from 10/24/2014 forward)


Earnings History for SciClone Pharmaceuticals (NASDAQ:SCLN)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/9/2016Q216$0.20$37.90 million$39.00 millionViewN/AView Earnings Details
5/10/2016Q116$0.19$33.60 million$36.50 millionViewListenView Earnings Details
3/10/2016Q415$0.30$41.10 million$42.90 millionViewListenView Earnings Details
11/9/2015Q315$0.12$0.26$40.61 million$42.90 millionViewN/AView Earnings Details
8/10/2015Q215$0.12$0.26$37.27 million$37.90 millionViewListenView Earnings Details
5/11/2015Q414$0.03$0.17$34.00 million$33.60 millionViewListenView Earnings Details
3/11/2015Q4$0.15$0.29$38.93 million$41.43 millionViewN/AView Earnings Details
11/10/2014Q314$0.12$0.17$34.90 million$34.30 millionViewN/AView Earnings Details
8/11/2014Q214$0.10$0.20$33.40 million$32.50 millionViewListenView Earnings Details
5/12/2014Q114$0.08$0.10$32.20 million$26.60 millionViewListenView Earnings Details
3/12/2014Q314$0.15$0.08$38.30 million$32.70 millionViewListenView Earnings Details
11/12/2013Q114$0.15$0.18$39.70 million$35.20 millionViewListenView Earnings Details
8/7/2013Q2 2013$0.11$0.09$33.30 million$29.81 millionViewListenView Earnings Details
4/1/2013Q4 2012$0.12$0.04$35.30 million$33.10 millionViewListenView Earnings Details
11/9/2012Q312$0.21$0.20$43.09 million$40.70 millionViewN/AView Earnings Details
8/8/2012$0.18$0.20ViewN/AView Earnings Details
5/9/2012$0.11$0.15ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for SciClone Pharmaceuticals (NASDAQ:SCLN)
Current Year EPS Consensus Estimate: $0.33 EPS
Next Year EPS Consensus Estimate: $0.68 EPS


Dividend History for SciClone Pharmaceuticals (NASDAQ:SCLN)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading History for SciClone Pharmaceuticals (NASDAQ:SCLN)
Insider Ownership Percentage: 7.63%
Institutional Ownership Percentage: 79.42%
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
10/17/2016Wilson Wai-Shun CheungCFOSell1,475$10.00$14,750.00View SEC Filing  
8/30/2016Nancy T ChangDirectorSell25,040$10.30$257,912.00View SEC Filing  
8/29/2016Wilson Wai-Shun CheungCFOSell1,872$10.35$19,375.20View SEC Filing  
8/17/2016Friedhelm BlobelCEOSell501,875$10.00$5,018,750.00View SEC Filing  
8/16/2016Wilson Wai-Shun CheungCFOSell7,802$10.62$82,857.24View SEC Filing  
3/28/2016Friedhelm BlobelCEOSell10,000$9.29$92,900.00View SEC Filing  
3/18/2016Friedhelm BlobelCEOSell10,000$9.09$90,900.00View SEC Filing  
3/7/2016Friedhelm BlobelCEOSell20,000$10.01$200,200.00View SEC Filing  
2/26/2016Friedhelm BlobelCEOSell10,000$9.98$99,800.00View SEC Filing  
1/4/2016Friedhelm BlobelCEOSell200$9.01$1,802.00View SEC Filing  
12/28/2015Friedhelm BlobelCEOSell10,000$9.17$91,700.00View SEC Filing  
12/17/2015Friedhelm BlobelCEOSell9,400$9.00$84,600.00View SEC Filing  
12/11/2015Friedhelm BlobelCEOSell600$9.00$5,400.00View SEC Filing  
12/4/2015Friedhelm BlobelCEOSell10,000$9.22$92,200.00View SEC Filing  
12/3/2015Lan XieCFOSell14,166$9.50$134,577.00View SEC Filing  
11/27/2015Friedhelm BlobelCEOSell10,000$9.24$92,400.00View SEC Filing  
11/10/2015Wilson Wai-Shun CheungCFOSell7,803$9.51$74,206.53View SEC Filing  
7/24/2015Friedhelm BlobelCEOSell10,000$9.68$96,800.00View SEC Filing  
7/17/2015Friedhelm BlobelCEOSell10,000$9.72$97,200.00View SEC Filing  
7/10/2015Friedhelm BlobelCEOSell10,000$9.21$92,100.00View SEC Filing  
7/6/2015Friedhelm BlobelCEOSell20,000$10.80$216,000.00View SEC Filing  
6/26/2015Friedhelm BlobelCEOSell10,000$9.29$92,900.00View SEC Filing  
6/19/2015Friedhelm BlobelCEOSell10,000$9.42$94,200.00View SEC Filing  
6/12/2015Chuncai MengVPSell3,007$9.23$27,754.61View SEC Filing  
6/12/2015Friedhelm BlobelCEOSell10,000$9.13$91,300.00View SEC Filing  
6/8/2015Hong ZhaoCEOSell10,000$9.23$92,300.00View SEC Filing  
6/5/2015Friedhelm BlobelCEOSell10,000$9.07$90,700.00View SEC Filing  
6/1/2015Richard J HawkinsDirectorSell4,570$9.27$42,363.90View SEC Filing  
5/29/2015Friedhelm BlobelCEOSell10,000$9.38$93,800.00View SEC Filing  
5/29/2015Richard J HawkinsDirectorSell10,430$9.32$97,207.60View SEC Filing  
5/26/2015Richard J HawkinsDirectorSell11,982$9.44$113,110.08View SEC Filing  
5/22/2015Friedhelm BlobelCEOSell10,000$9.40$94,000.00View SEC Filing  
5/18/2015Chuncai MengVPSell23,660$9.56$226,189.60View SEC Filing  
5/15/2015Lan XieCFOSell26,668$9.20$245,345.60View SEC Filing  
4/24/2015Friedhelm BlobelCEOSell10,000$9.07$90,700.00View SEC Filing  
4/10/2015Friedhelm BlobelCEOSell10,000$9.10$91,000.00View SEC Filing  
3/12/2015Wilson Wai-Shun CheungCFOSell7,803$9.07$70,773.21View SEC Filing  
12/11/2014Richard J HawkinsDirectorSell15,591$8.80$137,200.80View SEC Filing  
9/2/2014Lan XieCFOSell36,468$6.97$254,181.96View SEC Filing  
8/15/2014Nancy T ChangDirectorBuy25,040$6.00$150,240.00View SEC Filing  
5/16/2014Hong ZhaoCEOSell12,500$4.75$59,375.00View SEC Filing  
8/22/2013Min YinVPSell10,938$5.50$60,159.00View SEC Filing  
8/20/2013Min YinVPSell12,500$5.50$68,750.00View SEC Filing  
2/28/2013Friedhelm BlobelCEOBuy3,000$3.86$11,580.00View SEC Filing  
(Data available from 1/1/2013 forward)


Latest Headlines for SciClone Pharmaceuticals (NASDAQ:SCLN)
News IconInsiders Pruning Their Holdings in SciClone Pharmaceuticals, Inc. (NASDAQ:SCLN) - CSZ News (NASDAQ:SCLN) - October 24 at 6:54 PM
News IconDimensional Fund Advisors LP Acquires 4,739 Shares of SciClone ... - DailyQuint (NASDAQ:SCLN) - October 23 at 11:24 AM
News IconBlackRock Advisors LLC reduces its investment in SciClone Pharmaceuticals Inc. (SCLN) - DailyQuint (NASDAQ:SCLN) - October 19 at 2:26 PM
News IconSciClone Pharmaceuticals, Inc. (NASDAQ:SCLN) Updated Broker Price Targets - The De Soto Edge (NASDAQ:SCLN) - October 17 at 12:29 PM logoSciClone Pharmaceuticals, Inc. (NASDAQ:SCLN) Deferred Tax Assets At $0.299 - (NASDAQ:SCLN) - October 17 at 12:29 PM
News IconBroker Changes For SciClone Pharmaceuticals, Inc. (NASDAQ:SCLN) - NewsDen (NASDAQ:SCLN) - October 12 at 7:09 PM logoSciClone Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : SCLN-US : October 11, 2016 (NASDAQ:SCLN) - October 11 at 7:33 PM
News IconInsiders are Curtailing Holdings in SciClone Pharmaceuticals, Inc. (NASDAQ:SCLN) - CSZ News (NASDAQ:SCLN) - October 10 at 6:42 PM
News IconAnalyst Coverage: SciClone Pharmaceuticals, Inc. (NASDAQ:SCLN) - NewsDen (NASDAQ:SCLN) - October 3 at 11:50 AM
News IconUpgrades And Downgrades For SciClone Pharmaceuticals, Inc. (NASDAQ:SCLN) - NewsDen (NASDAQ:SCLN) - September 30 at 2:58 PM logoSciClone Pharmaceuticals, Inc. – Value Analysis (NASDAQ:SCLN) : September 29, 2016 (NASDAQ:SCLN) - September 29 at 12:36 PM logoSciClone Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : SCLN-US : September 28, 2016 (NASDAQ:SCLN) - September 28 at 12:27 PM logoSciClone Pharmaceuticals : Announces Progress In Advancing Clinical Pipeline For China Pharmaceuticals Market (NASDAQ:SCLN) - September 27 at 11:50 AM logoSciClone Announces Progress In Advancing Clinical Pipeline For China Pharmaceuticals Market - PR Newswire (press release) (NASDAQ:SCLN) - September 26 at 8:01 AM logoSciClone Announces Progress In Advancing Clinical Pipeline For China Pharmaceuticals Market (NASDAQ:SCLN) - September 26 at 8:01 AM
News IconSafe Haven Investment Portfolio Stocks: Gilead Sciences (NASDAQ:GILD), SciClone Pharmaceuticals (NASDAQ:SCLN) - Street Wise Report (press release) (blog) (NASDAQ:SCLN) - September 19 at 11:46 AM
News IconStock Down Over the Last Quarter: SciClone Pharmaceuticals, Inc ... - Post News (NASDAQ:SCLN) - September 18 at 11:23 AM logoSoligenix, Inc. (SNGX), SciClone Pharma (SCLN) Enter SGX942 Development, Distribution Agreement - (NASDAQ:SCLN) - September 12 at 11:56 AM logoSoligenix and SciClone Establish Regional Licensing Agreement for SGX942, a Novel Product Candidate for Oral Mucositis (NASDAQ:SCLN) - September 12 at 11:56 AM logoSoligenix (SNGX) and SciClone (SCLN) Establish Regional Licensing Agreement for SGX942, a Novel Product Candidate for Oral Mucositis (NASDAQ:SCLN) - September 12 at 11:56 AM
News IconStock Struggling for the Quarter: SciClone Pharmaceuticals, Inc. (NASDAQ:SCLN) - Post News (NASDAQ:SCLN) - September 4 at 11:12 AM logoAccounts Payable For SciClone Pharmaceuticals, Inc. (NASDAQ:SCLN) Is $2.6 - (NASDAQ:SCLN) - September 4 at 11:12 AM logoSciClone To Present At Two Investor Conferences In September 2016 (NASDAQ:SCLN) - September 1 at 7:09 PM logoETF’s with exposure to SciClone Pharmaceuticals, Inc. : August 31, 2016 (NASDAQ:SCLN) - August 31 at 12:33 PM
News IconSciClone Pharmaceuticals, Inc. (NASDAQ:SCLN) Analysts Recommendations and Insider Trading - The Independent Republic (NASDAQ:SCLN) - August 24 at 6:59 PM logoSciClone Pharmaceuticals, Inc. (NASDAQ:SCLN) Reports Accounts ... - (NASDAQ:SCLN) - August 22 at 11:52 AM
News IconCerulean Pharma Inc (NASDAQ:CERU) Stock Plunged on August 18 (NASDAQ:SCLN) - August 20 at 11:18 AM logoSciclone Pharmaceuticals Inc (SCLN) President & CEO Friedhelm Blobel Sold $5 million of Stocks (NASDAQ:SCLN) - August 19 at 10:12 AM logoSCICLONE PHARMACEUTICALS INC Financials (NASDAQ:SCLN) - August 18 at 7:33 PM logoSciClone Pharmaceuticals, Inc. (NASDAQ:SCLN) Trading Down – Insiders Are Selling (NASDAQ:SCLN) - August 17 at 10:19 AM logoInsiders Are Selling - SciClone Pharmaceuticals, Inc. (NASDAQ:SCLN) - Finance Daily (NASDAQ:SCLN) - August 16 at 7:26 PM logoETF’s with exposure to SciClone Pharmaceuticals, Inc. : August 16, 2016 (NASDAQ:SCLN) - August 16 at 7:25 PM logoSciClone Pharmaceuticals, Inc. :SCLN-US: Earnings Analysis: Q2, 2016 By the Numbers : August 15, 2016 (NASDAQ:SCLN) - August 15 at 7:42 PM logoSciClone Reports Second Quarter 2016 Financial Results (NASDAQ:SCLN) - August 9 at 7:36 PM logoSciClone posts 2Q profit (NASDAQ:SCLN) - August 9 at 7:36 PM logoQ2 2016 SciClone Pharmaceuticals Inc Earnings Release - Time Not Supplied (NASDAQ:SCLN) - August 9 at 10:32 AM logoSCICLONE PHARMACEUTICALS INC Files SEC form 8-K, Financial Statements and Exhibits (NASDAQ:SCLN) - August 3 at 7:41 PM logoTraders Actions to Focus: SciClone Pharmaceuticals, Inc. (NASDAQ ... - Street Updates (NASDAQ:SCLN) - August 1 at 11:56 AM logoSciClone Pharmaceuticals, Inc. (NASDAQ:SCLN) Yearly Accounts Payable At $4.495 Millions - (NASDAQ:SCLN) - July 30 at 6:35 PM logoSciClone Pharmaceuticals To Report Second Quarter 2016 Financial Results On August 9, 2016 (NASDAQ:SCLN) - July 28 at 6:00 AM logoAccounts Payable For SciClone Pharmaceuticals, Inc. (NASDAQ:SCLN) Stood At $3.267 - (NASDAQ:SCLN) - July 24 at 11:21 AM logoSciClone Pharmaceuticals Inc. (SCLN) is Trading Higher on Unusual Volume for July 21 - (NASDAQ:SCLN) - July 23 at 11:06 AM
News IconChecking in on Stock Volatility for: SciClone Pharmaceuticals, Inc. (NASDAQ:SCLN) - Engelwood Daily (NASDAQ:SCLN) - July 22 at 7:05 PM
News IconSciclone Pharmaceuticals (NASDAQ:SCLN) Short Interest Decreased By 2.6% - Press Telegraph (NASDAQ:SCLN) - July 22 at 7:05 PM logoSciClone Pharmaceuticals Inc. (SCLN) Dropped After Strategic Review Concluded - RTT News (NASDAQ:SCLN) - July 22 at 7:05 PM
News IconTrading Action Review: Watching Unusual Volume on SciClone Pharmaceuticals, Inc. (NASDAQ:SCLN) - Engelwood Daily (NASDAQ:SCLN) - July 21 at 10:09 AM
News IconTraders Alert – SciClone Pharmaceuticals, Inc. (NASDAQ:SCLN) - Financial Breaking News (press release) (NASDAQ:SCLN) - July 21 at 10:09 AM logoYesterday Trends to Watch: Express Scripts (ESRX) , SciClone Pharmaceuticals, (SCLN) - Street Updates (NASDAQ:SCLN) - July 21 at 10:09 AM
News IconSciClone Pharmaceuticals, Inc. (NASDAQ:SCLN) Spurns Buyout Offers - Scibility Media (NASDAQ:SCLN) - July 21 at 10:09 AM logoSciClone Pharmaceuticals Inc. (SCLN) Drops 20.81% on July 19 - (NASDAQ:SCLN) - July 21 at 10:09 AM


SciClone Pharmaceuticals (NASDAQ:SCLN) Chart for Monday, October, 24, 2016

Last Updated on 10/24/2016 by Staff